We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
1Research Scholar, Maharishi Arvind Institute of Pharmacy, Jaipur, Rajasthan, India
2Associate Professor, Maharishi Arvind Institute of Pharmacy, Jaipur, Rajasthan, India
3Principal, Maharishi Arvind Institute of Pharmacy, Jaipur, Rajasthan, India
Non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic liver disease (MASLD), represents the hepatic manifestation of metabolic syndrome and is the leading cause of chronic liver disease globally. The disease spectrum extends from simple steatosis (NAFL) to non-alcoholic steatohepatitis (NASH), progressive fibrosis, cirrhosis, and hepatocellular carcinoma. Given the multi-targeted pathomechanisms of NAFLD—including insulin resistance, lipid dysregulation, oxidative stress, and pro-inflammatory signaling—herbal therapeutics have gained substantial interest. Plants belonging to the genus Ficus (family Moraceae), notably Ficus amplissima, are rich sources of bioactive flavonoids, polyphenols, and terpenoids that exhibit protective metabolic effects. This review synthesizes current insights into the pathophysiology of NAFLD, evaluates natural dietary and herbal interventions, and highlights the therapeutic mechanisms of Ficus amplissima in mitigating hepatic steatosis, dyslipidemia, oxidative stress, and structural liver injury.
1. Introduction and Epidemiology
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions characterized by lipid accumulation exceeding 5% of liver weight in individuals without excessive alcohol consumption or secondary causes of steatosis. Globally, NAFLD affects approximately 25%–30% of the adult population, with rising prevalence in parallel with global obesity and type 2 diabetes mellitus (T2DM) epidemics. While lifestyle modifications—including dietary calorie restriction and exercise—remain the cornerstone of management, long-term patient compliance is notoriously low. Furthermore, pharmacotherapeutic options directly approved for liver-specific protection in NAFLD remain limited, driving research toward plant-derived natural compounds capable of multi-target physiological regulation.
2. Pathophysiology
The progression of simple steatosis to NASH and advanced fibrosis is described by the "multiple-hit" hypothesis, replacing the outdated "two-hit" model.
3. Phytochemical Strategies and Natural Products in NAFLD
Plant-derived bioactives act on multiple signaling nodes in the liver, offering systemic protective benefits:
|
Class |
Key Compounds |
Primary Molecular Targets / Mechanisms |
|
Flavonoids |
Quercetin, Rutin, Epicatechin |
Activates AMPK/PPAR-α
|
|
Phenolic Acids |
Gallic acid, Ferulic acid, Chlorogenic acid |
Reduces hepatic lipid uptake; enhances endogenous glutathione (GSH) and Catalase (CAT). |
|
Alkaloids |
Berberine |
Enhances insulin sensitivity; activates AMPK pathway; reduces serum triglycerides and LDL. |
|
Terpenoids & Steroids |
Ursolic acid, Lupeol, β
|
Suppresses hepatic inflammatory responses; downregulates lipogenic enzymes. |
4. The Potential of Genus Ficus with Focus on Ficus amplissima
The genus Ficus (Moraceae family) comprises over 800 species distributed throughout tropical and subtropical regions. Species such as Ficus religiosa, Ficus racemosa, and Ficus carica have demonstrated substantial hypolipidemic, hypoglycemic, and anti-inflammatory activities. Ficus amplissima Smith, an ethnomedicinal plant native to India, contains a rich profile of bioactive secondary metabolites:
5. Summary of Pharmacological Evidence for Ficus amplissima
Experimental evaluation in combined streptozotocin (STZ) and high-fat diet (HFD) preclinical models demonstrates the multi-target efficacy of Ficus amplissima leaf extract:
CONCLUSION
Natural products, particularly rich flavonoid sources like Ficus amplissima, represent promising multi-target candidates for managing complex metabolic conditions like NAFLD. Future directions include:
Preclinical toxicological safety profiling and translational clinical trials to determine human efficacy and dosage regimens.
REFERENCES
Arshi Khan*, Richa Agarwal, Rajesh Asija, Natural Therapeutics in Non-Alcoholic Fatty Liver Disease: A Comprehensive Review, Int. J. Med. Pharm. Sci., 2026, 2 (11), 82-84. https://doi.org/10.5281/zenodo.24413580
10.5281/zenodo.24413580